These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16891466)

  • 1. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
    Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
    Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
    Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
    Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
    Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
    Luo Y; Lin C; Zhang XY; Liang X; Fu M; Feng FY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):660-3. PubMed ID: 20021860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
    Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
    Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
    Giovannetti E; Mey V; Nannizzi S; Pasqualetti G; Marini L; Del Tacca M; Danesi R
    Mol Pharmacol; 2005 Jul; 68(1):110-8. PubMed ID: 15795320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.
    Bessho Y; Oguri T; Ozasa H; Uemura T; Sakamoto H; Miyazaki M; Maeno K; Sato S; Ueda R
    Oncol Rep; 2009 Jan; 21(1):263-8. PubMed ID: 19082471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
    Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
    J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
    Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.